Quick Answer
ALX ONCOLOGY HOLDINGS INC reported Long-Term Debt of $4.53 million for fiscal year 2025.
ALX ONCOLOGY HOLDINGS INC Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $4.53M | -52.1% |
| 2024 | $9.47M | -1.8% |
| 2023 | $9.64M | +2.7% |
| 2022 | $9.39M | +73.2% |
| 2019 | $5.42M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.76M | -41.4% | -17.6% |
| June 30, 2025 | $7.00M | -28.4% | -15.0% |
| March 31, 2025 | $8.23M | -15.2% | -13.1% |
| December 31, 2024 | $9.47M | -1.8% | -3.7% |
| September 30, 2024 | $9.84M | +2.7% | +0.7% |
| June 30, 2024 | $9.77M | +2.7% | +0.7% |
| March 31, 2024 | $9.70M | +2.7% | +0.7% |
| December 31, 2023 | $9.64M | +2.7% | +0.7% |
- ALX ONCOLOGY HOLDINGS INC showed a decrease of -52.1% in Long-Term Debt compared to the prior fiscal year.
- Over the 2019–2025 period, ALX ONCOLOGY HOLDINGS INC’s long-term debt has declined by 16.4% (from $5.42 million to $4.53 million).
- The most recent figure is from ALX ONCOLOGY HOLDINGS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: